Actively Recruiting
Contribution of Brain Positron Emission Tomography With 18F-Flurodeoxyglucose for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
Led by Central Hospital, Nancy, France · Updated on 2025-02-03
20
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on distinguishing the cause of cognitive disorders in adults, specifically whether these disorders stem from psychiatric conditions or neurodegenerative diseases. The study addresses the challenge that both conditions can appear similar but have different outcomes and care needs. The increasing prevalence of these disorders makes accurate diagnosis important for improving patient and caregiver quality of life. The study evaluates the use of brain positron emission tomography (PET) with 18F-flurodeoxyglucose in diagnosing cognitive impairment. This imaging technique is assessed to see how well it helps in identifying whether cognitive decline is due to psychiatric or neurodegenerative origins. Participants undergo PET scans as part of their care to provide data for analysis. Participants with cognitive impairment will be observed, and their clinical data collected, including PET imaging results. Researchers will measure the ability of the PET scan to differentiate types of cognitive disorders in one day. The study involves no treatment and mainly collects data to improve diagnosis. Participation lasts through the imaging and data collection process, with no additional follow-up mentioned.
CONDITIONS
Brief Title
Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with cognitive impairment
- Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care
You will not qualify if you...
- Patients objecting to the collection of their data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo brain positron emission tomography with 18F-Flurodeoxyglucose as part of their routine care to help differentiate the origin of cognitive disorders.
1 visit (in-person)
Duration - Up to the study completion date
Participants who undergo routine care are observed to monitor the progression or stability of cognitive disorders.
Visits according to routine care schedules
Trial Site Locations
Total: 1 location
1
Nancy's hospital
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Research Team
A
Antoine VERGER, MD, PhD
V
VERONIQUE ROCH, MSc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here